Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.
After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NVO -1.54%) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years.
Novo Nordisk should withstand competition from new Eli Lilly diabetes drug, says Wall Street bank
JP Morgan is optimistic about Novo Nordisk (NYSE:NVO) despite competition from Eli Lilly's new drug, orforglipron. Its analysts reckon Novo will hold its ground if Lilly's upcoming trial results match Novo's existing treatments.
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Buying quality stocks when they're unpopular can be very rewarding.
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk (NVO 5.03%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (HIMS -18.26%).
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said. The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35.4% year-on-year despite competition from Mounjaro. In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations.
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new hypertension drug from KBP in 2023.
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Shares of weight loss and diabetes medication maker Novo Nordisk NYSE: NVO have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close.
2 Important Insights From Novo Nordisk's Earnings Call
Pharmaceutical giant Novo Nordisk (NVO -1.22%) released its fourth-quarter and full-year earnings report on Feb. 5. The Denmark-based company performed pretty well, leading to a post-earnings jump in its stock price.
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NVO -3.62%). The two companies have approved weight loss drugs that are generating billions in revenue, and there's still much more growth on the horizon.
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk (NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling another 2.6% through 10:10 a.m.
